[go: up one dir, main page]

WO1998010744A1 - Composition comportant un agent antiviral ou antibacterien destinee a empecher la transmission de maladies - Google Patents

Composition comportant un agent antiviral ou antibacterien destinee a empecher la transmission de maladies Download PDF

Info

Publication number
WO1998010744A1
WO1998010744A1 PCT/GB1997/002455 GB9702455W WO9810744A1 WO 1998010744 A1 WO1998010744 A1 WO 1998010744A1 GB 9702455 W GB9702455 W GB 9702455W WO 9810744 A1 WO9810744 A1 WO 9810744A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
genital
bacterial
viral
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1997/002455
Other languages
English (en)
Inventor
Simon Everard Barton
James Richard Smith
Philip David Kell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9619091.3A external-priority patent/GB9619091D0/en
Priority claimed from GBGB9705844.0A external-priority patent/GB9705844D0/en
Application filed by Individual filed Critical Individual
Priority to AU42144/97A priority Critical patent/AU4214497A/en
Publication of WO1998010744A1 publication Critical patent/WO1998010744A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams

Definitions

  • This invention relates to prophylactic compositions. Since the onset of the AIDS epidemic, there has been increasing emphasis on the promotion of so-called "safe sex". The surrounding educational efforts have largely concentrated on the promotion of the male condom which provides reasonable protection against transmission of HIV infection during conventional sexual activities.
  • an object of the present invention to provide a prophylactic composition useful in reducing the transmission of sexually-transmitted diseases (STD) and transmission of diseases by orogenital sexual contact.
  • STD sexually-transmitted diseases
  • composition which is useful also in reducing the risk of sexual transmission of pathogens during genital to genital and genital to manual sexual contact.
  • compositions of the invention can be formulated to have an effect extending over the duration of sexual contact. Thus, protection is provided for the necessary period required.
  • compositions can be formulated so as to be effective against viral and bacterial STDs and other viruses and bacteria which might be transmitted in the course of sex, in particular oral sex, e.g. hepatitis B and human papilloma virus.
  • a range of anti- viral agents exist and include, e.g. polyethylene glycol alkylphenylethers such as the nonyl and octyl homologues marketed under the trade names " onoxynol” and "Octoxynol” and di-isobutyl phenoxy polyethoxyethanol. These agents are non-ionic surfactants and are believed to owe their virucidal activity to their ability to disrupt viral membrane integrity.
  • the anti-bacterial or anti-viral agents should generally be present in an amount of from about 0.05 to 0.2 percent by weight, typically about 0.1 percent.
  • the anti- viral agent should be present in an amount of at least about 0.25%.
  • Anti-bacterial agents should preferably be included in the compositions of the invention along with the anti-viral agents.
  • the anti-bacterial agent When used together with the anti-viral agent, the anti-bacterial agent should preferably be present in a concentration of at least 0.05%, preferably at 0.1%.
  • Typical anti-bacterial agents include quaternary ammonium salts, such as benzalkonium chloride and cetrimide, imidazoles, such as metronidazole, clotrimazole, and miconazole, and antiseptics such as chlorhexidine acetate and gluconate.
  • composition comprises a viscous, shghtly sticky material, having a viscosity and physical properties very similar to that of natural sahva.
  • Such materials are currently available on the market as synthetic sahvas and one commercial composition is available under the trade name "Sahva Orthana", manufactured by A. S. Orthana Kemisk Fabrik, Denmark.
  • the composition is based on natural mucin extracted from pigs stomachs.
  • Synthetic sahvas are currently prescribed for patients having eating, swallowing and speech difficulties, caused by a reduction in the production of natural sahvas e.g. by cancer of the head and neck region.
  • the anti-bacterial and/or anti-viral agent is dispersed in an effective amount in the synthetic sahva.
  • a vehicle simulating natural sahva as a carrier for the anti-bacterial and/or anti-viral agent is thought to aid greater adhesion of the active ingredient to the mucosa, whether in the mouth, vagina or anus.
  • the resulting composition may be packaged in single dose sachets containing about 2.5 ml of the liquid prophylactic composition. For example, just before sexual contact is anticipated, the passive partner can break the sachet and spread the synthetic sahva around the mouth.
  • Other methods can break the sachet and spread the synthetic sahva around the mouth.
  • the material include a water-soluble or chewable capsule or tablet.
  • the ingredients will include hydrophihc materials or materials causing a rapid break-up of the tablet and the formation of a coating of synthetic saliva on the buccal and lingual surfaces.
  • the compositions of the invention are packaged in an aerosol can or oral spray container.
  • the spray container may be fitted with a metering pump so that the user sprays a measured amount of say 2-5 mis into the mouth.
  • prophylactic composition of the present invention for use of the prophylactic composition of the present invention in reducing transmission of diseases transmitted by genital/genital or genital/manual contact, alternative delivery/packaging systems may be preferred, in particular where the composition is to be applied, initially, to non-mucosal surfaces such as the hands.
  • compositions of the invention One example of a typical formulation for the compositions of the invention is given below :-
  • the manufacturing formula for the preparation of 1 litre is:
  • Nonoxynol-9 (Cilag Ltd). 3 g
  • the mucin solution can be replaced by carboxymethyl cellulose in an amount of about 10 g of the sohd material per htre of the made up composition.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compositions prophylactiques qui fournissent une protection efficace contre la transmission de l'infection due au VIH lors des activités sexuelles. Lesdites compositions sont basées sur une salive synthétique et comportent un agent virocide et de préférence également un agent antibactérien.
PCT/GB1997/002455 1996-09-12 1997-09-10 Composition comportant un agent antiviral ou antibacterien destinee a empecher la transmission de maladies Ceased WO1998010744A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU42144/97A AU4214497A (en) 1996-09-12 1997-09-10 Composition comprising an antiviral or antibacterial agent for preventing transmission of diseases

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9619091.3A GB9619091D0 (en) 1996-09-12 1996-09-12 Oral prophylactic compositions
GB9619091.3 1996-09-12
GBGB9705844.0A GB9705844D0 (en) 1997-03-21 1997-03-21 Oral prophyllactic compositions
GB9705844.0 1997-03-21

Publications (1)

Publication Number Publication Date
WO1998010744A1 true WO1998010744A1 (fr) 1998-03-19

Family

ID=26310033

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1997/002455 Ceased WO1998010744A1 (fr) 1996-09-12 1997-09-10 Composition comportant un agent antiviral ou antibacterien destinee a empecher la transmission de maladies

Country Status (3)

Country Link
AU (1) AU4214497A (fr)
GB (1) GB2318292A (fr)
WO (1) WO1998010744A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003047610A1 (fr) * 2001-12-03 2003-06-12 Herturn, L.L.C. Composition permettant d'augmenter la libido et d'ameliorer la satisfaction sexuelle, et procede associe
US20130108679A1 (en) * 2011-10-31 2013-05-02 Aletheian Innovations Limited Personal care composition

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0351301A2 (fr) * 1988-07-11 1990-01-17 Societe Anonyme S S P L Safe Sex Products Licensing Composition pharmaceutique pour la prévention des maladies sexuellement transmissibles
WO1992016201A1 (fr) * 1991-03-22 1992-10-01 E.B. Michaels Research Associates, Inc. Procede servant a inactiver le sperme et les virus a enveloppe
EP0636374A2 (fr) * 1993-07-28 1995-02-01 JOHNSON & JOHNSON CONSUMER PRODUCTS, INC. Composition lubrifiante spermicide antivirale
WO1995008981A1 (fr) * 1993-09-29 1995-04-06 The Medical College Of Hampton Roads On Behalf Of The Conrad Program Compositions contraceptives
CA2132688A1 (fr) * 1994-09-22 1996-03-23 George Martyn Livingston Composition spermicide antiseptique et methode d'application

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9101076L (sv) * 1991-04-10 1992-10-11 Camurus Ab Saliversaettningsmedel
CZ293891A3 (cs) * 1991-09-26 1993-04-14 Chovanec Dalibor SALIDAL spray - umělé sliny
JP3151767B2 (ja) * 1992-11-02 2001-04-03 千寿製薬株式会社 人工唾液
GB9408545D0 (en) * 1994-04-29 1994-06-22 Zyma Sa Compositions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0351301A2 (fr) * 1988-07-11 1990-01-17 Societe Anonyme S S P L Safe Sex Products Licensing Composition pharmaceutique pour la prévention des maladies sexuellement transmissibles
WO1992016201A1 (fr) * 1991-03-22 1992-10-01 E.B. Michaels Research Associates, Inc. Procede servant a inactiver le sperme et les virus a enveloppe
EP0636374A2 (fr) * 1993-07-28 1995-02-01 JOHNSON & JOHNSON CONSUMER PRODUCTS, INC. Composition lubrifiante spermicide antivirale
WO1995008981A1 (fr) * 1993-09-29 1995-04-06 The Medical College Of Hampton Roads On Behalf Of The Conrad Program Compositions contraceptives
CA2132688A1 (fr) * 1994-09-22 1996-03-23 George Martyn Livingston Composition spermicide antiseptique et methode d'application

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003047610A1 (fr) * 2001-12-03 2003-06-12 Herturn, L.L.C. Composition permettant d'augmenter la libido et d'ameliorer la satisfaction sexuelle, et procede associe
US20130108679A1 (en) * 2011-10-31 2013-05-02 Aletheian Innovations Limited Personal care composition

Also Published As

Publication number Publication date
GB9719266D0 (en) 1997-11-12
AU4214497A (en) 1998-04-02
GB2318292A (en) 1998-04-22

Similar Documents

Publication Publication Date Title
EP1263411B1 (fr) Compositions et leurs utilisation permettant de piéger et d'inactiver les microbes pathogènes et les spermatozoïdes
KR970705976A (ko) 항-성병 제형의 조성물 및 이의 용도(use and composition of an anti-sexually transmitted diseases formulation)
JP2004505028A (ja) 粘膜炎、口内炎およびベーチェット症候群などの湿性上皮表面の疼痛性、炎症性および潰瘍性症状の治療のための医薬組成物
US6828308B2 (en) Compositions and methods for the treatment or prevention of inflammation
AU2001243431A1 (en) Compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa
JPH0774164B2 (ja) 伝染性性病予防薬剤
JPH06505700A (ja) 外膜をもつウィルスおよび精子を不活性化する方法
US6624198B1 (en) AIDS prophylactic lubricating composition and devices for its use
US20020151521A1 (en) Universal antiviral composition
US5778886A (en) Vaginal compositions combining a spermicidal agent and a peroxygen compound
US5646189A (en) Prevention of HIV infection
CN116615180A (zh) 用于治疗和/或预防病毒感染的羟基磷灰石组合物
WO1998010744A1 (fr) Composition comportant un agent antiviral ou antibacterien destinee a empecher la transmission de maladies
US8518434B2 (en) Antiseptic spermicidal composition and means for its application
US6302108B1 (en) Spermicidal and viricidal compositions
EP0992238B1 (fr) Utilisation de triclosan pour la prevention et le traitement de la mucosite
EP3888629A1 (fr) Composition pour le traitement ou la prévention d'une infection par un virus
BE1018740A3 (nl) Samenstelling voor de behandeling van vochtige epitheliale oppervlakken.
CA2132688A1 (fr) Composition spermicide antiseptique et methode d'application
WO2000072839A1 (fr) Composition spermicide antiseptique et son instrument d'application
US20050025847A1 (en) Microbicidal compositions and method of use
EP4304738B1 (fr) Composition pour le traitement ou la prévention d'une infection par le coronavirus
CN101249084B (zh) 可预防性传播疾病的消毒组方
US20050241645A1 (en) Composition for preventing the transmission of human immunodeficiency syndrome virus
ITMI982686A1 (it) Composizioni orali in forma di colluttorio o gel a base di chitosano,acido glicirrizico o suoi sali e olio di melaleuca alternifolia.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CH JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 09254701

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998513375

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase